Concepts (172)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neurodevelopmental Disorders | 3 | 2021 | 619 | 0.980 |
Why?
|
| Neurological Rehabilitation | 1 | 2024 | 8 | 0.850 |
Why?
|
| Recovery of Function | 2 | 2017 | 450 | 0.790 |
Why?
|
| Craniocerebral Trauma | 3 | 2022 | 144 | 0.670 |
Why?
|
| Encephalitis | 2 | 2023 | 120 | 0.660 |
Why?
|
| Glial Fibrillary Acidic Protein | 2 | 2019 | 108 | 0.600 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2019 | 19 | 0.600 |
Why?
|
| Child Abuse | 3 | 2022 | 223 | 0.600 |
Why?
|
| Meningoencephalitis | 1 | 2019 | 20 | 0.600 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2019 | 38 | 0.590 |
Why?
|
| Population Surveillance | 1 | 2021 | 397 | 0.560 |
Why?
|
| Autoantibodies | 2 | 2023 | 466 | 0.520 |
Why?
|
| Hashimoto Disease | 1 | 2017 | 31 | 0.520 |
Why?
|
| Nervous System Diseases | 1 | 2021 | 403 | 0.500 |
Why?
|
| Physical Therapy Modalities | 1 | 2017 | 53 | 0.500 |
Why?
|
| Coronavirus Infections | 1 | 2021 | 366 | 0.490 |
Why?
|
| Athletic Injuries | 1 | 2017 | 69 | 0.480 |
Why?
|
| Astrocytes | 1 | 2019 | 288 | 0.480 |
Why?
|
| Status Epilepticus | 1 | 2017 | 157 | 0.460 |
Why?
|
| Brain Injuries | 2 | 2024 | 712 | 0.450 |
Why?
|
| Brain Concussion | 1 | 2017 | 240 | 0.420 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 92 | 0.390 |
Why?
|
| Child | 18 | 2026 | 26307 | 0.340 |
Why?
|
| Injury Severity Score | 3 | 2017 | 230 | 0.320 |
Why?
|
| Brain Diseases | 2 | 2023 | 305 | 0.320 |
Why?
|
| Critical Illness | 2 | 2024 | 616 | 0.290 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2022 | 3916 | 0.270 |
Why?
|
| Fever | 2 | 2022 | 312 | 0.270 |
Why?
|
| Neurocognitive Disorders | 2 | 2018 | 75 | 0.270 |
Why?
|
| Ophthalmoplegia, Chronic Progressive External | 1 | 2026 | 8 | 0.240 |
Why?
|
| Acyl-CoA Dehydrogenase, Long-Chain | 1 | 2026 | 15 | 0.240 |
Why?
|
| Kearns-Sayre Syndrome | 1 | 2026 | 10 | 0.240 |
Why?
|
| Lipid Metabolism, Inborn Errors | 1 | 2026 | 30 | 0.240 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2025 | 14 | 0.230 |
Why?
|
| Humans | 29 | 2026 | 131759 | 0.220 |
Why?
|
| Seizures, Febrile | 1 | 2025 | 31 | 0.220 |
Why?
|
| Muscular Diseases | 1 | 2026 | 124 | 0.220 |
Why?
|
| Adolescent | 11 | 2026 | 20987 | 0.210 |
Why?
|
| DNA, Mitochondrial | 1 | 2026 | 241 | 0.210 |
Why?
|
| Clinical Protocols | 1 | 2025 | 228 | 0.210 |
Why?
|
| Neuroimaging | 4 | 2022 | 404 | 0.210 |
Why?
|
| Mitochondrial Diseases | 1 | 2026 | 149 | 0.210 |
Why?
|
| Microglia | 1 | 2025 | 138 | 0.200 |
Why?
|
| Dexamethasone | 1 | 2025 | 262 | 0.200 |
Why?
|
| Epilepsy | 2 | 2022 | 890 | 0.200 |
Why?
|
| Nerve Net | 2 | 2017 | 267 | 0.190 |
Why?
|
| Ascaridoidea | 1 | 2022 | 5 | 0.190 |
Why?
|
| Ascaridida Infections | 1 | 2022 | 5 | 0.190 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2025 | 303 | 0.190 |
Why?
|
| Continuity of Patient Care | 1 | 2024 | 143 | 0.190 |
Why?
|
| Diffuse Axonal Injury | 1 | 2022 | 10 | 0.190 |
Why?
|
| Meningitis | 1 | 2022 | 98 | 0.180 |
Why?
|
| Spinal Injuries | 1 | 2022 | 33 | 0.180 |
Why?
|
| Male | 16 | 2026 | 65274 | 0.180 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2025 | 274 | 0.180 |
Why?
|
| Language Development Disorders | 1 | 2022 | 178 | 0.170 |
Why?
|
| Nervous System | 1 | 2021 | 123 | 0.170 |
Why?
|
| Patient Discharge | 2 | 2022 | 507 | 0.170 |
Why?
|
| Exanthema | 1 | 2022 | 74 | 0.170 |
Why?
|
| Child, Preschool | 7 | 2025 | 15051 | 0.160 |
Why?
|
| Cartilage Diseases | 1 | 2020 | 17 | 0.160 |
Why?
|
| Kidney Transplantation | 1 | 2026 | 572 | 0.160 |
Why?
|
| Encephalomyelitis, Acute Disseminated | 1 | 2020 | 10 | 0.160 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2022 | 181 | 0.160 |
Why?
|
| Spinal Cord Ischemia | 1 | 2020 | 30 | 0.160 |
Why?
|
| White Matter | 1 | 2022 | 231 | 0.160 |
Why?
|
| Embolism | 1 | 2020 | 39 | 0.160 |
Why?
|
| Infant | 7 | 2022 | 13317 | 0.160 |
Why?
|
| Disease Progression | 3 | 2022 | 2221 | 0.160 |
Why?
|
| Hematoma, Subdural | 1 | 2019 | 28 | 0.150 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 2019 | 24 | 0.150 |
Why?
|
| Brain Waves | 1 | 2019 | 43 | 0.150 |
Why?
|
| Botulism | 1 | 2018 | 9 | 0.150 |
Why?
|
| Time Factors | 2 | 2021 | 6280 | 0.150 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2022 | 226 | 0.140 |
Why?
|
| Cranial Nerve Diseases | 1 | 2018 | 28 | 0.140 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2018 | 14 | 0.140 |
Why?
|
| Critical Care | 1 | 2024 | 680 | 0.140 |
Why?
|
| Autistic Disorder | 1 | 2022 | 398 | 0.140 |
Why?
|
| Leukopenia | 1 | 2018 | 45 | 0.140 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2022 | 493 | 0.140 |
Why?
|
| Interdisciplinary Studies | 1 | 2017 | 5 | 0.130 |
Why?
|
| Rehabilitation Centers | 1 | 2017 | 27 | 0.130 |
Why?
|
| Female | 15 | 2026 | 71214 | 0.130 |
Why?
|
| Neutropenia | 1 | 2018 | 205 | 0.130 |
Why?
|
| Child Development | 1 | 2019 | 273 | 0.130 |
Why?
|
| Brain | 3 | 2022 | 3235 | 0.130 |
Why?
|
| Post-Concussion Syndrome | 1 | 2017 | 50 | 0.130 |
Why?
|
| Patient Readmission | 1 | 2020 | 423 | 0.120 |
Why?
|
| Cerebral Cortex | 1 | 2019 | 468 | 0.120 |
Why?
|
| Neural Pathways | 1 | 2017 | 286 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1912 | 0.110 |
Why?
|
| Telemedicine | 1 | 2022 | 523 | 0.110 |
Why?
|
| Retrospective Studies | 6 | 2023 | 17662 | 0.110 |
Why?
|
| Age Factors | 1 | 2021 | 2872 | 0.110 |
Why?
|
| Stroke | 1 | 2022 | 1049 | 0.100 |
Why?
|
| Language Development | 1 | 2013 | 36 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1406 | 0.100 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2017 | 314 | 0.100 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1405 | 0.100 |
Why?
|
| Neuropsychological Tests | 1 | 2017 | 998 | 0.100 |
Why?
|
| Disability Evaluation | 1 | 2013 | 197 | 0.100 |
Why?
|
| Infant, Newborn | 3 | 2022 | 8594 | 0.100 |
Why?
|
| Retinal Telangiectasis | 1 | 2012 | 2 | 0.090 |
Why?
|
| Cerebellar Diseases | 1 | 2012 | 78 | 0.090 |
Why?
|
| Alexander Disease | 1 | 2011 | 2 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2013 | 955 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 5297 | 0.090 |
Why?
|
| Medulla Oblongata | 1 | 2011 | 21 | 0.090 |
Why?
|
| Telomere-Binding Proteins | 1 | 2012 | 44 | 0.090 |
Why?
|
| Walking | 1 | 2013 | 234 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2026 | 12993 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2017 | 5122 | 0.080 |
Why?
|
| Intellectual Disability | 1 | 2017 | 1082 | 0.080 |
Why?
|
| Telomere | 1 | 2012 | 220 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 1965 | 0.080 |
Why?
|
| Hospitals | 2 | 2022 | 445 | 0.070 |
Why?
|
| Length of Stay | 1 | 2013 | 1399 | 0.070 |
Why?
|
| Cerebellum | 1 | 2011 | 462 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2017 | 3696 | 0.070 |
Why?
|
| Seizures | 2 | 2022 | 890 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2013 | 3451 | 0.060 |
Why?
|
| Abnormalities, Multiple | 1 | 2012 | 974 | 0.060 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2025 | 12 | 0.060 |
Why?
|
| Injections, Spinal | 1 | 2025 | 132 | 0.060 |
Why?
|
| Hospitalization | 1 | 2013 | 1942 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1518 | 0.050 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 36 | 0.050 |
Why?
|
| Oligodendroglia | 1 | 2023 | 80 | 0.050 |
Why?
|
| Amitriptyline | 1 | 2022 | 27 | 0.050 |
Why?
|
| Histiocytic Necrotizing Lymphadenitis | 1 | 2022 | 4 | 0.050 |
Why?
|
| KCNQ2 Potassium Channel | 1 | 2022 | 43 | 0.050 |
Why?
|
| Pancytopenia | 1 | 2022 | 40 | 0.040 |
Why?
|
| Lymphadenopathy | 1 | 2022 | 32 | 0.040 |
Why?
|
| Gain of Function Mutation | 1 | 2022 | 114 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2022 | 110 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 3416 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2025 | 933 | 0.040 |
Why?
|
| Paresthesia | 1 | 2020 | 9 | 0.040 |
Why?
|
| Intervertebral Disc Degeneration | 1 | 2020 | 17 | 0.040 |
Why?
|
| Syndrome | 1 | 2023 | 1170 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2022 | 209 | 0.040 |
Why?
|
| Muscle Weakness | 1 | 2020 | 90 | 0.040 |
Why?
|
| Cervical Vertebrae | 1 | 2020 | 116 | 0.040 |
Why?
|
| Mandibulofacial Dysostosis | 1 | 2017 | 12 | 0.030 |
Why?
|
| Peripheral Nervous System | 1 | 2017 | 46 | 0.030 |
Why?
|
| Aggression | 1 | 2019 | 221 | 0.030 |
Why?
|
| Codon, Nonsense | 1 | 2017 | 141 | 0.030 |
Why?
|
| Limb Deformities, Congenital | 1 | 2017 | 117 | 0.030 |
Why?
|
| Executive Function | 1 | 2017 | 136 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2017 | 178 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2017 | 286 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2020 | 793 | 0.030 |
Why?
|
| Autism Spectrum Disorder | 1 | 2019 | 442 | 0.030 |
Why?
|
| Texas | 1 | 2022 | 3622 | 0.030 |
Why?
|
| Phenotype | 1 | 2023 | 4528 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2017 | 1457 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2017 | 1235 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 934 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 4052 | 0.020 |
Why?
|
| Muscle Hypotonia | 1 | 2012 | 194 | 0.020 |
Why?
|
| Biomarkers | 1 | 2019 | 3407 | 0.020 |
Why?
|
| Aging | 1 | 2017 | 1266 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 769 | 0.020 |
Why?
|
| Histones | 1 | 2012 | 533 | 0.020 |
Why?
|
| Base Sequence | 1 | 2012 | 2783 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 3616 | 0.020 |
Why?
|
| United States | 1 | 2022 | 11812 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 1745 | 0.010 |
Why?
|
| Adult | 1 | 2026 | 31700 | 0.010 |
Why?
|
| Animals | 1 | 2022 | 34404 | 0.010 |
Why?
|
| Mutation | 1 | 2011 | 6194 | 0.010 |
Why?
|